Topic
6 facts from 1 episode, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2026
Daphne Koller said insitro's first drug, for the fatty liver disease MASH, would enter the clinic the year after the panel.
“Our first drug is heading into the clinic next year. Um, it's in the disease called MASH, which is a terrible fatty liver disease.”
Undated
Daphne Koller said the transformer model originated in industrial research, as an example of industry's role in recent AI inventions.
“going back to the transformers model, it's all really originated in industrial research”
Undated
Daphne Koller said over 90% of drugs that enter clinical testing fail in clinical trials.
“where over 90% of drugs that go into the clinic end up failing in clinical trials”
Undated
Daphne Koller said competitors in physical AI have no shortcuts and must build custom hardware, data and models, which she described as a competitive moat.
“You have to build the custom hardware, you have to collect the custom data, you have to build the custom models that understand the physical world and causality.”
Undated
Daphne Koller said more than 70 ALS drugs have entered clinical trials, four have been approved, and they extend lifespan by only a couple of months.
“Seventy plus drugs have gone into clinical trials, four have been approved. They extend lifespan by maybe a couple of months.”
Undated
Daphne Koller said the UK government and the Wellcome Trust funded the UK Biobank, a dataset open to researchers at modest cost.
“the UK government made and the Wellcome Trust made a very big investment in creating a data that is pretty much open to any researcher for very modest economic outlay.”
Episodes